SCHEMBL10147129

SCHEMBL10147129

CCOC(=O)c1cc2cccc(Cl)c2nc1[C@H](C)NC(=O)OC(C)(C)C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.40
ALDH1A1 P00352 2/20 0.40
KDM4E B2RXH2 1/20 0.40
GAA P10253 1/20 0.40
PKM P14618 1/20 0.40
HPGD P15428 1/20 0.40
ALOX12 P18054 1/20 0.40
ABCB1 P08183 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
TP53 P04637 2/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
AAK1 Q2M2I8 1/20 0.37
CRHBP P24387 1/20 0.36
CRHR2 Q13324 1/20 0.36
LMNA P02545 1/20 0.36
BDKRB1 P46663 1/20 0.36
MAOA P21397 1/20 0.36
MAOB P27338 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1694817 0.88 ABCB1 (0.39) ALDH1A1HPGDABCB1SMN1; SMN2AAK1
SCHEMBL10146887 0.88 ABCB1 (0.39) ALDH1A1HPGDABCB1SMN1; SMN2AAK1
SCHEMBL1694884 0.87 MAPT (0.39) MAPTHPGDTP53SMN1; SMN2AAK1
SCHEMBL10147646 0.87 MAPT (0.39) MAPTHPGDTP53SMN1; SMN2AAK1
SCHEMBL1695142 0.78 ABCB1 (0.39) MAPTALDH1A1KDM4EGAAHPGD
SCHEMBL18653749 0.77 TRPA1 (0.44) MAPTALDH1A1KDM4EGAAPKM
SCHEMBL10146918 0.77 TSHR (0.57) ALDH1A1KDM4EHPGDABCB1
SCHEMBL21445289 0.77 TP53 (0.42) MAPTALDH1A1HPGDTP53SMN1; SMN2
SCHEMBL10146874 0.74 MAPT (0.39) MAPTALDH1A1HPGDTP53AAK1
SCHEMBL1694878 0.74 MAPT (0.39) MAPTALDH1A1HPGDTP53AAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130085131-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2013-04-04 US disclosed
US-20130085131-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2013-04-04 US disclosed
WO-2012003274-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY AMGEN INC. (US) 2012-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130085131-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES MCL1, SSB, BCL9 MAPT 1990/4885ALDH1A1 3436/4885KDM4E 1440/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.